Parabilis Medicines IPO
Parabilis Medicines is a biotechnology company focused on developing novel therapeutics for serious diseases. The company works on advancing drug candidates through clinical development with the goal of addressing unmet medical needs. Investors monitor biotech IPOs like Parabilis for breakthrough therapies and commercial potential.
Key Facts
| Industry | Biotechnology |
| Founded | Not publicly disclosed |
| Headquarters | Not publicly disclosed |
| Funding | Completed IPO in June 2026, raising $670 million (potentially $745 million with overallotment) at $20 per share, valuing the company at approximately $2.3 billion. The offering was significantly upsized from initial targets of $413M-$476M and set a record as the largest biotech IPO. Backed by Regeneron. |
About Parabilis Medicines
Parabilis Medicines is a biotechnology company working to develop therapeutic solutions for patients with serious medical conditions. Like many biotech companies, Parabilis likely focuses on specific disease areas where there are significant unmet medical needs and opportunities to develop differentiated treatment approaches.
Biotechnology companies typically advance drug candidates through preclinical studies and multiple phases of clinical trials before seeking regulatory approval. This process requires substantial capital investment, which often necessitates raising funds through private financing rounds and eventually public markets.
The path to an IPO for biotechnology companies depends on multiple factors including clinical progress, competitive landscape, intellectual property position, and the strength of the management team. Companies in this sector often go public to fund late-stage clinical development and prepare for potential product commercialization.
IPO Status
Parabilis Medicines, a Cambridge-based biotechnology company focused on peptide-based therapeutics, completed its initial public offering in June 2026, setting a record for the largest biotech IPO. The company priced its shares at $20 per share and raised $670 million in an upsized offering, significantly exceeding its initial filing target of $413-476 million. Some sources reported the total proceeds at $745 million, likely including overallotment options. The IPO valued the company at approximately $2.3 billion. The record-breaking offering will fund advancement of the company's lead peptide-based drug candidate into Phase 3 clinical trials for desmoid tumors, as well as support its broader pipeline targeting difficult-to-drug targets. With backing from Regeneron and significant investor interest that led to the upsized offering, Parabilis is now publicly traded and pursuing what its CEO described as their "own moonshot" in drugging traditionally undruggable targets. The substantial capital raise positions the company well for its late-stage clinical development programs.
Competitors
Frequently Asked Questions
Does Parabilis Medicines have a stock?
Parabilis Medicines has not had an IPO yet. The company remains privately held, and while it may be considering going public, no official IPO filing or announcement has been made. Sign up for alerts to stay informed.
When is the Parabilis Medicines IPO date?
No IPO date has been announced for Parabilis Medicines. The company has not filed an S-1 registration statement with the SEC, so the timing of any potential public offering remains uncertain. Sign up for alerts to stay informed.
How can I buy Parabilis Medicines stock?
Parabilis Medicines stock is not currently available for public purchase as the company has not completed an IPO. Once public, shares would be available through standard brokerage platforms. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts